Irinotecan HCl Trihydrate

製品コードS2217 別名:CPT-11 HCl Trihydrate

Irinotecan HCl Trihydrate化学構造

分子量(MW):677.18

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.

サイズ 価格(税別) 在庫  
In DMSO JPY 33500 あり
JPY 13600 あり
JPY 36800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(30)

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.
特性 Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.
ターゲット
Topo I [1]
体外試験

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. [1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. [2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. [3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse bone marrow cell NW\keVhLS3m2b4TvfIlkcXS7IHHzd4F6 MULDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDic45mKG2jcoLve{Bk\WyuIHL5JGNHXS2JTTDhd5NigS5iSVO1NF0xNjByMTFOwG0> MVKyNVM1OTZ5NB?=
PC3 cells MnvrR5l1d3SxeHnjbZR6KGG|c3H5 MYW3NkBp NXv3WIdKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlA1KM7:TR?= M3vT[|IyOzRzNke0
A375 cells NEPIdHFEgXSxdH;4bYNqfHliYYPzZZk> MkHmO|IhcA>? MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeT6gTWM2OD1yLkC0JO69VQ>? NFPafIgzOTN2MU[3OC=>
LNCAP cells NGDrVGREgXSxdH;4bYNqfHliYYPzZZk> MmLuO|IhcA>? NF3xbJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4xQSEQvF2= NVTwVnJkOjF|NEG2O|Q>
MESSA cells MojiR5l1d3SxeHnjbZR6KGG|c3H5 MnH6O|IhcA>? MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXNUSSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6wNUDPxE1? MlzFNlE{PDF4N{S=
H460 cells M1THWmN6fG:2b4jpZ4l1gSCjc4PhfS=> MYS3NkBp MnX5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6wNVUh|ryP MmDiNlE{PDF4N{S=
MES-SA/Dx5 cells MlTKR5l1d3SxeHnjbZR6KGG|c3H5 M2joblczKGh? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LjDJR|UxRTBwMEKyJO69VQ>? NUHJ[ZpOOjF|NEG2O|Q>
H69 cells M2fLTGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWC2NHZJPzJiaB?= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LjDJR|UxRTBwMEKyJO69VQ>? M1m4[lIyOzRzNke0
IGROV1 cells MkPtR5l1d3SxeHnjbZR6KGG|c3H5 MUS3NkBp MlTnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTWdTV1ZzIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlA{KM7:TR?= MkXjNlE{PDF4N{S=
SK-MEL-2 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= NEL4THQ4OiCq MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4yKM7:TR?= NFvNOoYzOTN2MU[3OC=>
MALME-3M cells NWSyfmtxS3m2b4TvfIlkcXS7IHHzd4F6 NVyyR2FrPzJiaB?= M1TFOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1CVE2HLUPNJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigS5iSVO1NF0xNjJizszN M4riUlIyOzRzNke0
DU145 cells M1zTUWN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml;NO|IhcA>? MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6yJO69VQ>? MWCyNVM1OTZ5NB?=
HT-29 cells M1rVemN6fG:2b4jpZ4l1gSCjc4PhfS=> MVi3NkBp Mni1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MkBKSzVyPUCuNlIh|ryP NGDlS3UzOTN2MU[3OC=>
H69AR cells NE\NR3NEgXSxdH;4bYNqfHliYYPzZZk> MWO3NkBp M1TyNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg3QUGUIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJG1FWjFiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NiCLQ{WwQVAvOjVizszN NIPM[mozOTN2MU[3OC=>
MCF7 cells M1PYNGN6fG:2b4jpZ4l1gSCjc4PhfS=> NHnZe4gzPCCq M1v6dWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XlwIFnDOVA:OC53IN88US=> MUKyOlg1OTF4OB?=
HCT116 M1rJN2Z2dmO2aX;uJIF{e2G7 NVO4SpE3S2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgZ5l1d3SxeHnjbZR6KGGpYXnud5QhUEOWMUG2MEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgLJRigG:uLYLld4l{fGGwdDmgZZQh[SCmcoXnJINwdmOnboTyZZRqd25icILv[JVkcW6pIEWwKUBqdmirYnn0bY9vKG:oIHPvcI9vgSCob4LtZZRqd25wIFnDOVA:OC53NDFOwG0> MofvNVE6PjV|NkK=
RPMI8402 NVvm[|ZIS3m2b4TvfIlkcXS7IHHzd4F6 MlPhOEBl[Xm| MmTHR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ibIntdIhw[myjc4SgeJVud3JiY3XscEBtcW6nIGLQUWk5PDB{IHHmeIVzKDRiZHH5d{Bw\iC2cnXheI1mdnRwIFnDOVA:OC53NzFOwG0> M1:3T|EzPzR5N{m4
KB3-1 cells NXz4RolVS3m2b4TvfIlkcXS7IHHzd4F6 M4DEXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGK7IF3UWEBu\XSqb3SuJGlEPTB;MD62PEDPxE1? NXHE[JRlOTh5N{G5N|A>
PC3 cells NUThW3luWHKxbHnm[ZJifGmxbjDhd5NigQ>? MVK3NkBp MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtfWyjcjDEUmEh[2:wdHXueEBi\nSncjC3NkBpenNiYomgR5lSXUGQVDDOSkBndHWxcnXzZ4Vv[2ViYYPzZZkvKEmFNUC9NE45KM7:TR?= MXKyOlc{OTNyMB?=
A549 cells NXPvTpdUS3m2b4TvfIlkcXS7IHHzd4F6 M{HROVI1KGh? Mn7iR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WUzDhd5NigS5iSVO1NF0xNjhizszN MkLLNlY5PDFzNki=
MCF7 cells MnXpVJJwdGmoZYLheIlwdiCjc4PhfS=> NYHvO4E3QTZiaB?= NV3NR|U{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHz1cIFzKESQQTDjc451\W62IHHmeIVzKDl4IHjyd{BjgSCFeWHVRW5VKE6IIH\seY9z\XOlZX7j[UBie3OjeT6gTWM2OD1yLkmg{txO MYGyOlc{OTNyMB?=
HepG2 cells M3vVW2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkXsNlQhcA>? M3:5TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7LjDJR|UxRTBwOTFOwG0> M{jEN|I3QDRzMU[4
MDA-MB-435 cells Ml3HR5l1d3SxeHnjbZR6KGG|c3H5 MYK3NkBp NHPvOGJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmuJGlEPTB;MT6xOEDPxE1? NFvsbnozODN5MUG4Ny=>
LS174T cells NVzz[GRLS3m2b4TvfIlkcXS7IHHzd4F6 NH;TWY06PiCq MkjwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHMyPzSWIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZkvKEmFNUC9NU4yPiEQvF2= NFP4b3oyQDVzM{m3Oi=>
T84 cells MWfQdo9tcW[ncnH0bY9vKGG|c3H5 M{D3OVk3KGh? MnLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWOESgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdHWuYYKgSG5CKGOxboTlcpQh[W[2ZYKgPVYhcHK|IHL5JGN6WVWDTmSgUmYh\my3b4Lld4NmdmOnIHHzd4F6NiCLQ{WwQVEvOiEQvF2= NVTBdGxQOjZ5M{GzNFA>
SW480 cells M4rQNWN6fG:2b4jpZ4l1gSCjc4PhfS=> M3\JblI1KGh? MnXLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3c1QDBiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XlwIFnDOVA:OS52IN88US=> M2HhUlI3QDRzMU[4
K562 cells NIjSd4JRem:uaX\ldoF1cW:wIHHzd4F6 M1TnXFczKGh? MmrmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{4hUUN3ME2xMlkh|ryP NFzzWWozPTR{MEG3OS=>
HT-29 cells MknxVJJwdGmoZYLheIlwdiCjc4PhfS=> NF30TGY4OiCq MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIHHzJINmdGy3bHHyJGRPSSClb370[Y51KGGodHXyJFczKGi{czDifUBEgVGXQV7UJG5HKG[udX;y[ZNk\W6lZTDhd5NigS5iSVO1NF0yNjlizszN M2f6elI3PzNzM{Cw
HCT116 cells NIr4eXJRem:uaX\ldoF1cW:wIHHzd4F6 MojqNlQuPzJiaB?= M17LfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEK0JJRwKDd{IHjyd{BjgSCVUlKgZZN{[XlwIFnDOVA:OiEQvF2= MmjtNlY2QTV6N{W=
Hep3B cells NYPMeZZmWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mm\jO|IhcA>? NIizTHVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmuJGlEPTB;ND63N{DPxE1? NULRNGUxOTl5OU[5OVY>
Hep3B cells MXXHdo94fGhiaX7obYJqfG:wIHHzd4F6 MXK3NkBp NInZZXVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\XB|QjDj[YxteyCjZoTldkA4OiCqcoOgZpkhYFSWIHHzd4F6NiCLQ{WwQVQvPzNizszN M1PXUlIzODd7MkW0
LoVo cells NIW4XGREgXSxdH;4bYNqfHliYYPzZZk> NE\CUlI4OiCq MkHHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUI9XdyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MkBKSzVyPUSuPVkh|ryP MWqyNFM4OTF6Mx?=
KBH5.0 cells MmHhR5l1d3SxeHnjbZR6KGG|c3H5 NGjt[o5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSkh3LkCgZ4VtdHNiYomgUXRVKG2ndHjv[E4hUUN3ME23MlQh|ryP MWSxPFc4OTl|MB?=
H3347 cells M4PJR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MX23NkBp M3nMTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg{OzR5IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDhd5NigS5iSVO1NF04NjV|IN88US=> MUOyOFU5OzN3NR?=
HCT15 cells M1Lh[3Bzd2yrZnXyZZRqd25iYYPzZZk> NVv4bnNzOjRvN{KgbC=> MnHwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB{NDD0c{A4OiCqcoOgZpkhW1KEIHHzd4F6NiCLQ{WwQVgvPSEQvF2= MYKyOlU6PTh5NR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AMPK / p-AMPK / mTOR / p-mTOR / p70S6K / p-p70S6K; 

PubMed: 25973791     


Western blot showing the protein levels of AMPK, p-AMPK, mTOR, p-mTOR, p70S6K, and p-p70S6K in LoVo and LoVo-R8 with or without irinotecan. 

NFκB p65 / phospho-NFκB p65 / NFκB p50 / IκBα / p27Kip1; 

PubMed: 22206574     


For Western blot analysis (B), cytoplasmic proteins were analyzed using antibodies against NFκB p65 and p50, phospho-NFκB p65, IκBα and p27Kip1. In the presence of irinotecan, there was a loss of cytoplasmic NF-κBp65, but in the presence of sorafenib, this loss was greatly reduced, corresponding to a decrease in phosphorylation of NF-κBp65. In addition, compared to treatment with sorafenib or irinotecan alone, there was increased expression of IκBα following treatment with sorafenib and irinotecan. Lastly, following treatment with irinotecan and sorafenib irinotecan combination, there was decreased expression of p27Kip1 compared to sorafenib treatment alone.

TopI / pAKT / pMEK / pERK / p-p38 MAPK / pJNK2; 

PubMed: 29237470     


a Gimatecan significantly inhibited the expression of TopI, pAKT, pMEK, and pERK, and activated the expression of p-p38 MAPK and pJNK2 in SNU-1 cells. b Gimatecan significantly inhibited the expression of pAKT and pERK in NCI-N87 cells. Cells were starved in serum-free medium overnight, exposed to gimatecan or irinotecan for 48 h and harvested at 70–80% confluence. Total protein of SNU-1 and NCI-N87 was extracted and the expression of TopI, pAKT, pMEK, pERK, p-p38 MAPK and pJNK2 were assessed by western-blotting 

25973791 22206574 29237470
Immunofluorescence
NFκB; 

PubMed: 22206574     


BT12 cells were incubated with sorafenib or vehicle for 30 minutes followed by treatment with irinotecan for an additional 2 hours. For indirect immunofluorescence (A), cells were fixed and stained with antibodies to NF-κB followed by fluorescent labeled secondary antibodies. Concurrent DAPI stain was used to localize the nuclei (lower panel). Slides were visualized using a fluorescent microscope and random fields were photographed. The cytoplasmic staining seen in untreated and sorafenib treated cells was significantly reduced following treatment with irinotecan. However, the addition of sorafenib enabled the cells to maintain cytoplasmic staining in the presence of irinotecan. 

22206574
Growth inhibition assay
Cell viability; 

PubMed: 25973791     


The sensitivity of eight colon cancer cell lines to irinotecan was measured using the CCK-8 assay. For the CCK-8 assay, cells were exposed to irinotecan at given concentrations for 72 h before measurement. The cell viability was presented as the percentage relative to untreated cells.

25973791
体内試験 In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. [5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. [6]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

- 合併
  • 細胞株: LoVo and HT-29 cells
  • 濃度: 0 μM -100 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.


    (参考用のみ)
動物試験:

[5]

- 合併
  • 動物モデル: Female nude mice with COLO 320 and WiDr xenografts.
  • 製剤: 0.9% NaCl
  • 投薬量: 20 mg/kg
  • 投与方法: Intraperitoneal injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (147.67 mM)
Ethanol 7 mg/mL (10.33 mM)
Water 1 mg/mL (1.47 mM)
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+saline
混合させたのち直ちに使用することを推奨します。
20mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 677.18
化学式

C33H38N4O6.HCl.3H2O

CAS No. 136572-09-3
保管
in solvent
別名 CPT-11 HCl Trihydrate

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04074343 Recruiting Drug: TAS-102|Drug: Irinotecan Gastric Adenocarcinoma|GastroEsophageal Cancer University of California Irvine|Taiho Pharmaceutical Co. Ltd. August 28 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Irinotecan HCl Trihydrateを買う | Irinotecan HCl Trihydrate ic50 | Irinotecan HCl Trihydrate供給者 | Irinotecan HCl Trihydrateを購入する | Irinotecan HCl Trihydrate費用 | Irinotecan HCl Trihydrate生産者 | オーダーIrinotecan HCl Trihydrate | Irinotecan HCl Trihydrate化学構造 | Irinotecan HCl Trihydrate分子量 | Irinotecan HCl Trihydrate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID